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ABSTRACT
Background. We aimed to examine whether pre-existing
impaired estimated glomerular ﬁltration rate (eGFR) and pro-
teinuriawere associated withmortality following community-ac-
quired pneumonia or sepsis among people aged ≥65 years with
diabetes mellitus, without end-stage renal disease.
Methods. Patients were followed up from onset of ﬁrst
community-acquired pneumonia or sepsis episode in a cohort
study using large, linked electronic health databases. Follow-up
was for up to 90 days, unlimited by hospital discharge. We used
generalized linear models with log link, normal distribution
and robust standard errors to calculate risk ratios (RRs) for
all-cause 28- and 90-day mortality according to two markers
of chronic kidney disease: eGFR and proteinuria.
Results. All-cause mortality among the 4743 patients with
pneumonia was 29.6% after 28 days and 37.4% after 90 days.
Among the 1058 patients with sepsis, all-cause 28- and 90-
day mortality were 35.6 and 44.2%, respectively. eGFR <30
mL/min/1.73 m2 was a risk marker of higher 28-day mortality
for pneumonia (RR 1.27: 95% CI 1.12–1.43) and sepsis (RR
1.32: 95% CI 1.07–1.64), adjusted for age, sex, socio-economic
status, smoking status and co-morbidities. Neither moderately
impaired eGFR nor proteinuria were associated with short-
term mortality following either infection.
Conclusions. People with pre-existing low eGFR but not on dia-
lysis are at higher risk of death following pneumonia and sepsis.
This association was not explained by existing co-morbidities.
These patients need to be carefully monitored to prevent modiﬁ-
able causes of death.
Keywords: chronic kidney disease, community-acquired
infections, electronic health records, infection/mortality,
proteinuria
INTRODUCTION
Chronic kidney disease (CKD) affects an estimated 1.8 million
people in England, 98% of whom do not require renal replace-
ment therapy [1]. CKD is deﬁned by reduced estimated glomeru-
lar ﬁltration rate (eGFR) or evidence of kidney damage such as
proteinuria and is commonest among older people [2, 3]. Most
patients with CKD are managed in primary care [4].
Infection is an important cause of mortality among older peo-
ple [5, 6]. Both reduced eGFR and proteinuria are associated with
an increased rate of infection-related mortality, which could be
partly explained by increased incidence of infection [7–9].
It is less clear whether CKD is also associated with poorer prog-
nosis following infection. When clinicians assess patients with
community-acquired infection, developing complications such
as acute kidney injury (AKI) may not yet be apparent, but they
will know which patients have pre-existing CKD. If pre-existing
CKD is a riskmarker for short-termmortality, thiswould be useful
for risk stratiﬁcation and clinicalmanagement of patients with in-
fections, especially in primary care where clinicians may not
have access to immediate laboratory tests. While the implica-
tions of acute changes in eGFR during infection are a focus of
current research, few studies have investigated the role of pre-
existing CKD [10]. Low baseline eGFR has been found to be as-
sociated with mortality following sepsis and community-ac-
quired pneumonia, but rarely examined according to
clinically meaningful categories of eGFR [11–15]. To the best
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of our knowledge, proteinuria has not been examined as a poten-
tial risk marker for mortality following infection [12, 15, 16].
Among older people, CKD frequently co-exists with other co-
morbidities [3]. An association of CKD with poor prognosis of
infections could thus be due to confounding from these
co-morbidities. For example, CKD is strongly associated with
cardiovascular disease, which may be complicated by infection,
resulting in post-infection mortality driven by the underlying
cardiovascular disease [17]. Such deaths would largely follow hos-
pitalization for cardiovascular events. CKD is associated with
healthcare-associated pneumonia, which carries a worse progno-
sis than community-acquired pneumonia [18, 19]. Focusing on
community-acquired infections should exclude infections arising
as short-term sequelae of cardiovascular events and improve
understanding of the relationship between pre-existing CKD
markers and infection prognosis.
Older people with diabetes mellitus form a large and growing
population in primary care who suffer a high incidence of com-
munity-acquired pneumonia and sepsis [20]. Forty per cent of
adults with diabetes have CKD, of whom three-quarters have
proteinuria, and CKD among these patients is associated with
a greater all-cause excess mortality than among patients without
diabetes [21]. If proteinuria is a risk marker for mortality among
older patients with diabetes who develop community-acquired
pneumonia or sepsis, this could inform clinical management
of a large primary care patient population with appreciable
mortality following infection [20].
This study aimed to examine whether baseline eGFR and
proteinuria were independent risk markers for short-termmor-
tality following community-acquired pneumonia or sepsis
among older people with diabetes mellitus, using large, linked
electronic health record databases.
MATERIALS AND METHODS
Data sources
The Clinical Practice Research Datalink (CPRD) is an anon-
ymized UK dataset, comprising primary care records (including
diagnoses, prescriptions and test results) for 12.8 million patients
in May 2011 when data were extracted. The CPRD population is
representative of the general UK population and validity of re-
corded diagnoses is generally high [22, 23]. Monitoring of eGFR
and proteinuria in primary care is standard practice for people
with diabetes and has been ﬁnancially incentivized by the Quality
Outcomes Framework since April 2004 [24].
Data linkage is available within England subject to practice-
level consent. Records of all patients in CPRD with available
linkage to Ofﬁce for National Statistics (ONS) mortality data
formed the study dataset [25]. We additionally used linked
Hospital Episodes Statistics admissions data, which were avail-
able for all patients [26].
Study population
The study population was a subset of a population described
in more detail previously [20]. It comprised people aged ≥65
years with diabetes mellitus who experienced a ﬁrst
community-acquired pneumonia or sepsis, with a valid serum
creatinine result and no history of renal replacement therapy.
A valid serum creatinine result was one recorded in primary
care after the latest time-point of diabetes diagnosis, 65th birth-
day, 1 year after patients’ practice registration, date the practice
reached CPRD quality control standards or 1 January 1998.
Study exit occurred at the ﬁrst time-point of death, patient leav-
ing the practice, last data collection from the practice, last ONS
data linkage date, renal replacement therapy (kidney transplant
or dialysis) or 31 March 2011. Patients with a history of renal re-
placement therapy were excluded.
Deﬁnition of infections
Infection was identiﬁed by a diagnostic Read code in primary
care records, or a diagnostic International Classiﬁcation of Dis-
ease 10 (ICD-10) code as the primary cause of hospital admission
in secondary care records. Theﬁrst consultation for infectionwas
treated as the date of infection onset. Any community-acquired
infection with onset at least 28 days after the ﬁrst valid serum
creatinine result, and before study exit, was included in the
study.
Hospital-acquired infections were identiﬁed and excluded as
described previously [20]. Brieﬂy, infections were designated as
hospital-acquired if onset was during or within 14 days of dis-
charge from a hospitalization. Hospital-acquired infections
continued until 28 days had passed without a diagnostic code
for the infection or 28 days after hospital discharge, whichever
was the later. After this, patients re-entered follow-up for com-
munity-acquired infection.
Study outcomes
The outcomes were death from any cause recorded in ONS
mortality data within 28 days (primary outcome) or within 90
days (secondary outcome) of infection onset.
Deﬁnition of CKD
CKDwas described in terms of eGFR and proteinuria, using
primary care records. We estimated eGFR from serum creatin-
ine test results using the CKD Epidemiology Collaboration
(CKD-EPI) equation including adjustment for ethnicity [27].
We excluded serum creatinine results <28 days prior to infec-
tion onset to avoid misclassiﬁcation of CKD status, as a devel-
oping infection could disrupt serum creatinine levels.
Clinically, CKD diagnosis is based on two GFR estimates at
least 3 months apart [2]. Using a single GFR estimate can result
in over-ascertainment of CKD due to creatinine ﬂuctuation [28].
If more than one serum creatinine result was recorded between
the start of patient follow-up and 28 days prior to infection onset,
we used the higher eGFR from the latest two results that were at
least 3 months apart, to obtain conservative estimates of eGFR
[28].
We aimed to categorize eGFR according to thresholds corre-
sponding to those used in diagnosing CKD stage. Due to the
small number of outcomes in the category eGFR < 15 mL/
min/1.73 m2, we collapsed Stages 4 and 5 to categorize eGFR
as < 30, 30–44, 45–59 and ≥60 mL/min/1.73 m2 [2].
A history of proteinuria was deﬁned by either a positive
urine protein test result (excluding results on the same day as
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a urinary tract infection diagnosis) or a diagnosis of proteinuric
renal disease. We did not count trace results as positive.
Other variables
Age was deﬁned in 5-year age-bands up to a ﬁnal category
of ≥85 years. Socio-economic status was assigned by quintile at
an individual level, using 2007 ONS estimates of the Index of
Multiple Deprivation, a composite area-level marker of depriv-
ation [25]. If this was not available, it was supplemented by
the socio-economic status for the patient’s primary care practice.
Smoking status was deﬁned by the most recent record before
infection onset when available, otherwise by the ﬁrst
subsequent record. Non-cardiovascular co-morbidities (chronic
lung disease, dementia, cancer, connective tissue disorders,
hypertension and cerebrovascular disease) and cardiovascular
co-morbidities (congestive heart failure and ischaemic heart dis-
ease) were deﬁned by diagnostic CPRD Read codes, and diabetic
medication history by CPRD prescription records prior to infec-
tion onset. HbA1C test results within 28 days before infection
were excluded as these could reﬂect disturbed glycaemic control
during the early stages of infection.
Data analysis
Pneumonia and sepsis analyses were conducted separately.
A patient could be included in both the pneumonia and sepsis
analyses if they experienced both infections, but not for mul-
tiple episodes of either pneumonia or sepsis. We excluded
patients with no smoking status or HbA1C result available.
We described mortality using Kaplan–Meier survival curves
stratiﬁed by eGFR status. We calculated risk ratios (RRs) using
a generalized linear model with log link, normal distribution
and robust standard errors, according to a pre-speciﬁed analysis
plan [29]. Our ﬁrst model adjusted for age, sex, socio-economic
status and infection onset prior to 1 April 2004 (when Quality
Outcomes Framework guidelines ﬁnancially incentivizing re-
cording of CKD status among people with diabetes in primary
care were introduced) [24]. Our second model adjusted for con-
founding by smoking status, characteristics of diabetes (HbA1C
and diabetic medication history) and non-cardiovascular co-
morbidities. Our ﬁnal model additionally adjusted for congestive
heart failure and ischaemic heart disease, which could confound
ormediate an association between CKD and post-infectionmor-
tality. We repeated the ﬁnal model with additional adjustment
for peripheral vascular disease as a sensitivity analysis.We looked
for effect modiﬁcation between eGFR and proteinuria in the ﬁnal
model.
We focused on whether pre-existing CKD was a risk marker
for short-term mortality following infection. Data on acute elec-
trolyte changes during infection were not routinely available, and
so potential causal mechanisms such as AKI could not be ex-
plored [30].
Causes of death in ONSmortality data are recorded using ICD-
10 codes from1 January 2001, and ICD-9 codes prior to this, which
are not easily comparable [31]. We therefore described cause of
death among patients who died after 1 January 2001.
Stata version 13.1 was used for data analysis. All code lists are
available on request.
Ethics
The study was approved by the Independent Scientiﬁc
Advisory Group of the CPRD (ISAC reference 11_033A) and
the London School of Hygiene & Tropical Medicine Ethics
Committee (LSHTM reference 6116).
RESULTS
We identiﬁed 4957 individuals with community-acquired
pneumonia and 1114 individuals with community-acquired
sepsis. Data were missing (for smoking status and/or HbA1C
results) for 212/4957 individuals with pneumonia (4.3%) and
56/1114 individuals with sepsis (5.0%). These patients were
excluded. Among patients with pneumonia, patients with miss-
ing data were older (median age 83 years, IQR: 78–88) com-
pared with those included (median age 80 years, IQR: 74–85),
with a higher 28-day mortality (excluded 88/214, 41.1%: in-
cluded 1406/4743, 29.6%) but a similar distribution of
baseline eGFR. A similar pattern was seen for sepsis.
Estimated GFR was based on the higher of two results for
4029 patients with pneumonia (84.9%) and 919 patients with
sepsis (86.9%); for the remaining patients, only a single valid
serum creatinine result was available. CKD prevalence was
high: almost half of the patients had eGFR <60 mL/min/1.73
m2 and a third had proteinuria. Patients with eGFR <60 mL/
min/1.73 m2 were older, with a higher prevalence of ischaemic
heart disease and congestive heart failure than patients with
eGFR ≥60 mL/min/1.73 m2 (Table 1).
Patients with pneumonia experienced 29.6% 28-day all-cause
mortality (1406 deaths). Patients with sepsis experienced 35.6%
28-day all-causemortality (377 deaths) (Table 2). Survival curves
showed highmortality at infection onset, declining over∼30 days
to amore stable rate for the next 60 days following both pneumo-
nia and sepsis (Figure 1). RRs for 28-day mortality were higher
among people with eGFR <30 mL/min/1.73 m2 compared with
people with eGFR ≥60 mL/min/1.73 m2 for pneumonia (RR =
1.27; 95% CI 1.10–1.47) and sepsis (RR = 1.42; 1.10–1.84), ad-
justed for age, sex, socio-economic status and onset prior to
April 2004. Adjustment for smoking status, co-morbidities
and characteristics of diabetes had minimal effect on these
RRs for pneumonia (fully adjusted RR = 1.27; 1.12–1.43) or
sepsis (fully adjusted RR = 1.32; 1.07–1.64). There was no evi-
dence of associations between intermediate levels of eGFR and
28-day mortality for either infection, nor for an association be-
tween proteinuria and 28-daymortality. The pattern of associa-
tions of eGFR and proteinuria with 90-day mortality was
similar to those for 28-day mortality (Table 2). Results were un-
changed by additional adjustment for peripheral vascular dis-
ease. There was no good evidence of effect modiﬁcation
between eGFR and proteinuria, and in particular no evidence
of any association of proteinuria with 28-day mortality within
any category of eGFR status (data not shown).
The underlying causes of death following pneumonia and
sepsis were similar for patients with eGFR above and below 60
mL/min/1.73 m2. Causes of 28-day mortality following sepsis
were predominantly sources of infection (Table 3). Following
O
R
IG
IN
A
L
A
R
T
IC
L
E
1004 H.I. McDonald et al.
pneumonia onset, pneumonia was recorded as an underlying or
contributory cause of death for 83.9% (1191/1419) of deaths
within 28 days and 76.3% (1366/1790) of deaths within 90
days. Among patients with eGFR <60 mL/min/1.73 m2, renal
disease was recorded as an underlying or contributory cause
for 10.6% (77/724) of those who died within 28 days of pneumo-
nia onset and 16.6% (152/913) of those who died within 90 days.
Recording of CKD as a cause of death increased with lower eGFR
(Table 4).
DISCUSSION
Among this population of older people with diabetes mellitus,
eGFR <30 mL/min/1.73 m2 was a risk marker of higher 28- and
90-day mortality following community-acquired pneumonia
and sepsis, compared with patients with eGFR ≥60 mL/min/
1.73 m2. The relationship between eGFR and mortality did
not change with adjustment for co-morbidities. Neither mod-
erately impaired eGFR nor proteinuria was associated with
higher short-term mortality following either infection.
The strengths of this study follow from the analysis of a fo-
cused question using large, linked datasets for a highly moni-
tored primary care population with a cohort study design.
Our study identiﬁes that the association between eGFR and
post-infection mortality persists when patients with end-stage
renal disease (ESRD) are excluded (and is not explained by
renal replacement therapy), when considering ﬁxed-term ra-
ther than in-hospital mortality (thus is not due to differences
in hospital stay) and when exclusively community-acquired in-
fections are considered (so does not result from increased risk of
healthcare-associated infections). The linked datasets allowed
us to identify infections both among patients presenting direct-
ly to hospital and thosemanaged in the community, maximized
ascertainment of mortality and enabled description of the
Table 1. Baseline characteristics of the study population
Pneumonia Sepsis
eGFR < 60 mL/min/1.73 m2 eGFR≥ 60 mL/min/1.73 m2 eGFR < 60 mL/min/1.73 m2 eGFR≥ 60 mL/min/1.73 m2
Age (years)
Median (IQR) 82 (77–87) 78 (72–83) 81 (75–86) 76 (71–82)
n (col %) n (col %) n (col %) n (col %)
Gender
Female 1231 (53.0) 1106 (42.0) 294 (55.7) 268 (45.7)
Onset prior to 1 April 2004 584 (25.1) 527 (20.0) 124 (23.5) 120 (20.5)
Socio-economic status (IMD quintile)a
1 (least deprived) 383 (16.5) 438 (16.6) 109 (20.6) 106 (18.1)
2 554 (23.8) 595 (22.6) 116 (22.0) 127 (21.7)
3 494 (21.3) 582 (22.1) 120 (22.7) 137 (23.4)
4 502 (21.6) 574 (21.8) 110 (20.8) 108 (18.4)
5 (most deprived) 391 (16.8) 444 (16.9) 73 (13.8) 108 (18.4)
Smoking status
Current 321 (13.8) 549 (20.9) 70 (13.3) 103 (17.6)
Ex-smoker 1185 (51.0) 1351 (51.3) 235 (44.5) 284 (48.5)
Non-smoker 776 (33.4) 698 (26.5) 207 (39.2) 193 (32.9)
Missing 42 (1.8) 35 (1.3) 16 (3.0) 6 (1.0)
Comorbidities
Chronic lung disease 503 (21.6) 686 (26.1) 59 (11.2) 95 (16.2)
Hypertension 1623 (69.8) 1662 (63.1) 372 (70.5) 381 (65.0)
Congestive heart failure 734 (31.6) 430 (16.3) 147 (27.8) 95 (16.2)
Ischaemic heart disease 966 (41.6) 887 (33.7) 223 (42.2) 207 (35.3)
Cerebrovascular disease 692 (29.8) 638 (24.2) 152 (28.8) 145 (24.7)
Other dementia 174 (7.5) 190 (7.2) 42 (8.0) 23 (3.9)
Cancer 382 (16.4) 474 (18.0) 99 (18.8) 120 (20.5)
Connective tissue disorders 228 (9.8) 215 (8.2) 36 (6.8) 52 (8.9)
HbA1C
Good <7% 1176 (50.6) 1401 (53.2) 251 (47.5) 308 (52.6)
Borderline 7–10% 966 (41.6) 1033 (39.2) 213 (40.3) 230 (39.3)
Poor >10% 108 (4.7) 131 (5.0) 41 (7.8) 34 (5.8)
None recorded 74 (3.2) 68 (2.6) 23 (4.4) 14 (2.4)
Prior antidiabetes medication
Insulin 122 (5.3) 126 (4.8) 34 (6.4) 23 (3.9)
Oral medications 1139 (49.0) 1426 (54.2) 247 (46.8) 312 (53.2)
Both 462 (19.9) 384 (14.6) 130 (24.6) 114 (19.5)
None 601 (25.9) 697 (26.5) 117 (22.2) 137 (23.4)
Total 2324 2633 528 586
eGFR, estimated glomerular ﬁltration rate.
aIndex of multiple deprivation (IMD) score for patient’s postcode where available, otherwise, practice-level IMD score.
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Table 2. Short-term mortality by CKD status (n = 4743 for pneumonia, n = 1058 for sepsis)a
Number
(column %)
28-Day
mortality
(row %)
90-Day
mortality
(row %)
RRs for 28-day mortality (95% CI) RRs for 90-day mortality (95% CI)
Adjusted for
demographics
b
adjusted for non-
CVD co-
morbidities
c
Fully adjusted
d
Adjusted for
demographics
b
Adjusted for non-
CVD co-
morbidities
c
Fully adjusted
d
Pneumonia
Proteinuria (adjusted for eGFR)
Yes 1611 (34.0) 499 (31.0) 625 (38.8) 1.07 (0.97–1.17) 1.07 (0.98–1.18) 1.07 (0.98–1.18) 1.05 (0.97–1.13) 1.06 (0.98–1.14) 1.05 (0.98–1.14)
No 3132 (66.0) 907 (29.0) 1150 (36.7) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference)
eGFR (mL/min/1.73 m2) (adjusted for proteinuria)
<30 <15 23 (0.5) 12 (52.2) 12 (52.2)
1.27 (1.10–1.47) 1.31 (1.13–1.52) 1.30 (1.12–1.52) 1.26 (1.12–1.42) 1.29 (1.14–1.45) 1.27 (1.12–1.43)
15–29 263 (5.6) 110 (41.8) 139 (52.9)
30–44 764 (16.1) 265 (34.7) 336 (44.0) 0.98 (0.86–1.10) 0.99 (0.88–1.13) 0.99 (0.88–1.12) 1.02 (0.93–1.13) 1.04 (0.94–1.15) 1.03 (0.94–1.14)
45–60 1162 (24.5) 332 (28.6) 418 (36.0) 0.91 (0.82–1.02) 0.94 (0.84–1.04) 0.93 (0.84–1.04) 0.91 (0.83–1.00) 0.93 (0.85–1.02) 0.92 (0.84–1.01)
≥60 2531 (53.4) 687 (27.1) 870 (34.4) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Total 4743 1406 (29.6) 1775 (37.4)
Sepsis
Proteinuria (adjusted for eGFR)
Yes 358 (33.8) 128 (35.8) 159 (44.4) 0.98 (0.82–1.17) 1.01 (0.85–1.21) 1.01 (0.85–1.21) 0.98 (0.86–1.13) 0.96 (0.84–1.10) 0.96 (0.84–1.10)
No 700 (66.2) 249 (35.6) 309 (44.1) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference)
eGFR (mL/min/1.73 m2) (adjusted for proteinuria)
<30 <15 8 (0.8) 2 (25.0) 5 (62.5)
1.42 (1.10–1.84) 1.41 (1.08–1.84) 1.37 (1.05–1.79) 1.39 (1.14–1.70) 1.32 (1.07–1.63) 1.32 (1.07–1.64)
15–29 62 (5.9) 32 (51.6) 39 (62.9)
30–44 190 (18.0) 88 (46.3) 103 (54.2) 1.25 (1.01–1.55) 1.24 (0.99–1.55) 1.24 (0.99–1.54) 1.14 (0.96–1.36) 1.12 (0.94–1.33) 1.11 (0.94–1.32)
45–60 232 (21.9) 76 (32.8) 95 (41.0) 0.95 (0.75–1.19) 0.91 (0.72–1.15) 0.91 (0.72–1.14) 0.92 (0.77–1.11) 0.89 (0.74–1.07) 0.89 (0.75–1.07)
≥60 566 (53.5) 179 (31.6) 226 (39.9) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Total 1058 377 (35.6) 468 (44.2)
aExcluding patients with missing smoking or HbA1C data.
bAge, gender, socio-economic status, onset prior to 1 April 2004.
cAge, gender, socio-economic status, onset prior to 1 April 2004, smoking status, chronic lung disease, dementia, cancer, connective tissue disorders, hypertension, cerebrovascular disease, diabetes medications, latest HbA1C.
dAge, gender, socio-economic status, onset prior to 1 April 2004, smoking status, chronic lung disease, dementia, cancer, connective tissue disorders, hypertension, cerebrovascular disease, diabetes medications, latest HbA1C, congestive heart failure,
ischaemic heart disease.
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Table 3. Top ﬁve underlying causes of death by ICD-10 code for short-term mortality following pneumonia and sepsis (deaths after 2001)
a
eGFR
eGFR <60 mL/min/1.73 m2 eGFR ≥60 mL/min/1.73 m2
28-Day mortality following pneumonia,
n = 1419
J18 Pneumonia, organism unspeciﬁed, n = 256, 35.4%
J44 Other chronic obstructive pulmonary disease,
n = 63, 8.7%
I25 Chronic ischaemic heart disease, n = 47, 6.5%
I50 Heart failure, n = 43, 5.9%
I64 Stroke, not speciﬁed as haemorrhage or infarction,
n = 37, 5.1%
J18 Pneumonia, organism unspeciﬁed, n = 216, 31.1%
J44 Other chronic obstructive pulmonary disease,
n = 63, 9.1%
I64 Stroke, not speciﬁed as haemorrhage or infarction,
n = 35, 5.0%
C34 Malignant neoplasm of bronchus and lung, n = 34,
4.9%
I25 Chronic ischaemic heart disease, n = 29, 4.2%
Total = 724 Total = 695
29–90Daymortality following pneumonia,
n = 371
J18 Pneumonia, organism unspeciﬁed, n = 38, 20.1%
I25 Chronic ischaemic heart disease, n = 24, 12.7%
J44 Other chronic obstructive pulmonary disease,
n = 13, 6.9%
C34 Malignant neoplasm of bronchus and lung, n = 12,
6.4%
I21 Acute myocardial infarction, n = 12, 6.4%
J18 Pneumonia, organism unspeciﬁed, n = 20, 11.0%
C34 Malignant neoplasm of bronchus and lung, n = 20,
11.0%
J44 Other chronic obstructive pulmonary disease,
n = 19, 10.4%
I25 Chronic ischaemic heart disease, n = 9, 5.0%
I64 Stroke, not speciﬁed as haemorrhage or infarction,
n = 9, 5.0%
Total = 189 Total = 182
28-Day mortality following sepsis, n = 387 N39 Other disorders of urinary systemb, n = 33, 15.9%
J18 Pneumonia, organism unspeciﬁed, n = 30, 14.4%
E14 Unspeciﬁed diabetes mellitus, n = 12, 5.8%
A41 Other sepsis, n = 11, 5.3%
L03 Cellulitis, n = 11, 5.3%
N39 Other disorders of urinary systemb, n = 20, 11.2%
A41 Other sepsis, n = 18, 10.1%
J18 Pneumonia, organism unspeciﬁed, n = 18, 10.1%
E14 Unspeciﬁed diabetes mellitus, n = 10, 5.6%
J44 Other chronic obstructive pulmonary disease, n = 6,
3.4%
=K55 Vascular disorders of intestine, n = 6, 3.4%
=L03 Cellulitis, n = 6, 3.4%
Total = 208 Total = 179
aDeaths prior to 2001 were recorded using ICD-9 codes and have not been included.
bAll incidences of code N39 were N39.0 Urinary tract infection, site not speciﬁed.
F IGURE 1 : Survival curves of short-term mortality following infection onset by eGFR status for (A) pneumonia and (B) sepsis.
Table 4. Recording of renal disease as a cause of deatha following pneumonia among patients with reduced eGFR
eGFR (mL/min/1.73 m2) Deaths within 28 days of pneumonia onset Deaths within 90 days of pneumonia onset
Total N18 CKD, n (%) Renal disease,b n (%) Total N18 CKD, n (%) Renal disease,b n (%)
<15 8 6 (75.0) 7 (87.5) 8 6 (75.0) 7 (87.5)
15–29 109 19 (17.4) 41 (37.6) 139 26 (18.7) 53 (38.1)
30–44 275 14 (5.1) 2 (15.3) 347 20 (5.8) 56 (16.1)
35–59 332 8 (2.4) 27 (8.1) 419 10 (2.4) 36 (8.6)
Total 724 47 (6.5) 77 (10.6) 913 62 (6.8) 152 (16.6)
aDeaths prior to 2001 were recorded using ICD-9 codes and have not been included.
bAny ICD-10 code from Chapter XIV ‘Diseases of the genitourinary system’ except N10 ‘Acute tubule-interstitial nephritis’, which is used for pyelonephritis, N30 ‘Cystitis’, N34 ‘Urethritis’
or N39.0 ‘Urinary tract infection, site not speciﬁed’.
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causes of death. The highly monitored population allowed good
ascertainment of CKD status. The cohort study design has less
potential for selection bias than an equivalent case–control
study.
A limitation is our assumption that the absence of a record
implies a negative status for proteinuria and co-morbidities.
Under-ascertainment of co-morbidities could result in residual
confounding, with unpredictable effects, but the high prevalence
of co-morbidities observed suggests that ascertainment was not
markedly incomplete. We observed a high prevalence of pro-
teinuria, and this is a highly monitored population (with ﬁnan-
cial incentives for standardized recording of proteinuria since
2004), but under-ascertainment of proteinuria could result in
underestimation of any association between proteinuria and
mortality [24]. Residual confounding from undiagnosed cardio-
vascular disease should have been minimized by adjustment for
cardiovascular disease risk factors including smoking, hyperten-
sion and characteristics of diabetes.
Our ﬁndings for eGFR provide further detail to build on pre-
vious ﬁndings that baseline eGFR <60 mL/min/1.73 m2 or
renal disease are risk factors for short-term mortality following
(hospital- or community-acquired) sepsis and for in-hospital
mortality following community-acquired pneumonia (includ-
ing patients receiving dialysis) [11–15]. A more comparable
Canadian study examined the associations between eGFR and
30-day mortality following community-acquired pneumonia
among the general population aged ≥65 years, excluding pa-
tients with ESRD [16]. Fully adjusted hazard ratios for 30-day
mortality were 1.22 (95% CI 1.01–1.49) for eGFR 45–59, 2.03
(1.64–2.50) for eGFR 30–44 and 4.94 (3.94–6.19) for eGFR <
30, compared with eGFR 60–104 mL/min/1.73 m2. These are
somewhat greater than the associations we observed. The differ-
ence may be explained by the different study populations. Both
studies required a baseline serum creatinine result for inclusion.
Our study population of older people with diabetes were rou-
tinely monitored for CKD (with ﬁnancial incentivization in pri-
mary care) [32]. Creatinine testing of the Canadian study
population may have been encouraged by co-morbidities or
health-behaviours associated with CKD (such as smoking),
which increase post-infection mortality, resulting in over-
estimation of the association of eGFR and post-infection mor-
tality. Our study population is less vulnerable to differential
ascertainment of CKD. Alternatively, the association between
eGFR and post-infection mortality may be smaller among
patients with diabetes.
To the best of our knowledge, our examination of any asso-
ciation between proteinuria and mortality following commu-
nity-acquired pneumonia and sepsis is novel. A history of
proteinuria, although a marker for mortality in general, does
not appear to be a risk marker for short-term mortality follow-
ing community-acquired infection. This is unlikely to be due to
chance, as the study was large, with ﬁndings consistent across
both infections.We designed our study to produce conservative
estimates and may have under-estimated the association be-
tween proteinuria and post-infection mortality due to under-
ascertainment of proteinuria. Alternatively, any potential rela-
tionship between proteinuria and mortality may have been mi-
tigated by clinical care of patients with infection who had pre-
existing proteinuria, for example, through swift recognition of
AKI.
The survival curves demonstrate a steep initial mortality fol-
lowing infection onset, and a high proportion of deaths had the
underlying cause assigned to infection. Since 2001 in England,
co-morbidities are assigned as the underlying cause of death
when pneumonia has occurred in the context of, for example,
malignancy or respiratory disease [25]. This suggests that the
associations we observed are driven by an association between
eGFR and infection prognosis, not merely high underlying
baseline mortality among patients with impaired eGFR. This
is supported by previous research which found 7.7-fold elevated
mortality in the 30 days following community-acquired pneu-
monia [19]. Estimates for associations between eGFR and mor-
tality were not substantially altered by adjustment for co-
morbidities, suggesting that any causal relationship between
eGFR and mortality is not mediated through co-morbidities.
Our ﬁndings apply to the large population of older patients
with community-acquired pneumonia or sepsis with diabetes
mellitus who do not have ESRD. Inclusion criteria are unlikely
to have limited generalizability appreciably. Practices which
consent to data linkage could be more research oriented, pro-
viding good primary care management of risk factors for
infection-related mortality (such as smoking cessation), but
this is unlikely to affect the relationship between CKD and
short-term mortality post-infection. Lack of pre-existing cre-
atinine test results is likely to reﬂect limited time potentially eli-
gible for the study rather than CKD status among this highly
monitored population. Missing data on smoking status and
HbA1C may be a marker of low patient engagement: caution
should be used in generalizing our results to patients who are
not actively managed in primary care.
We found that CKD is a useful clinical risk marker for post-
infectious mortality. Whether this relationship is causal is less
clear; but the association does not appear to be explained by age,
co-morbidities or hospital attendance. Potentialmechanisms in-
clude immune system dysfunction, but also more preventable
complications such as AKI. Combinations of risk factors may
be important: for example, patients with post-operative AKI
have higher mortality if they also have pre-existing CKD [30].
Our results have implications for patient management and
future research. Patients with baseline eGFR <30 mL/min/
1.73 m2 and community-acquired infection need careful mon-
itoring, particularly in the 28 days following infection. Future
research should investigate preventable mechanisms by which
low baseline eGFR could be related to post-infection mortality,
for example, ﬂuid management, AKI and drug dosage in pa-
tients with low renal clearance.
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